¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ : 2022-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ : 2022-06-17
±³À°ÀÏÀÚ : 2022-06-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È­»ó °­ÀÇ) ¹× ¼­¿ï·Ôµ¥È£ÅÚ 2, 3Ãþ 5°³·ë  
±³À°ÁÖÁ¦ : (¿Â∙¿ÀÇÁ¶óÀÎ º´Çà) Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  
À̸ÞÀÏ : cancer2@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 23 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 10¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 10¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 15¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 20¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 Room A 08:40~09:05 Unique needs and concerns of childhood cancer survivors  Yasushi Ishida(Ehime Prefectural Central Hospital, Japan) 
±³À°½Ã°£ 06-17 Room A 09:05~09:30 Building a cancer survivorship program  Miyako Tsuchiya(National Cancer Center, Japan) 
±³À°½Ã°£ 06-17 Room A 09:30~09:55 Integrating psycho-oncology to improve mental health for cancer survivors  Á¤¼®ÈÆ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 09:55~10:20 The effect of exercise on the QoL and survival in cancer survivors  Àü¿ë°ü(¿¬¼¼´ë) 
±³À°½Ã°£ 06-17 Room B 08:40~09:05 EGFR-targeted therapy  ÇÑÁö¿¬(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room B 09:05~09:30 HER2-targeted therapy  Shaheenah Dawood(Mohammed Bin Rashid University of Medicine and Health Sciences, UAE) 
±³À°½Ã°£ 06-17 Room B 09:30~09:55 Anti-angiogenetic therapy  Masafumi Ikeda(National Cancer Center Hospital East, Japan) 
±³À°½Ã°£ 06-17 Room B 09:55~10:20 RAS/RAF/MEK inhibitor  ÀÌÁö¿¬(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room D 08:40~09:05 What we have learned on oligometastasis   David Anthony Palma(London Health Science Center, Canada) 
±³À°½Ã°£ 06-17 Room D 09:05~09:21 Korean radiation oncologists  ÀÓäȫ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Room D 09:21~09:37 Korean medical oncologists  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room D 09:37~09:53 Management of oligometastasis from colorectal cancer  ÀÌÁ¾ÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room D 09:53~10:20 Locally aggressive RT for oligometastasis: SBRT & Hypo-Fx  Hak Choy(University of Texas Southwestern Medical Center, USA) 
È޽Ġ06-17  10:20~10:40 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 10:40~11:20 Pancreas Cancer – molecular diagnostics and therapeutics  Jeffrey A. Drebin(Memorial Sloan Kettering Cancer Center, USA) 
±³À°½Ã°£ 06-17 Room A 11:20~12:00 Clonal evolution in normal tissues  Seishi Ogawa(Kyoto University Graduate School of Medicine, Japan) 
±³À°½Ã°£ 06-17 Room D 11:20~11:40 Metastatic pancreatic cance  ¹ÌÁ¤() 
½Ä»ç 06-17  12:00~12:30 ½Ä»ç  () 
±³À°½Ã°£ 06-17 Room A 12:30~13:10 Recent updates of CDK4/6i data  ¹ÌÁ¤() 
±³À°½Ã°£ 06-17 Room D 12:30~13:10 Today & Tomorrow of EGFRm NSCLC: From early to advanced stage  ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë) 
È޽Ġ06-17  13:10~13:25 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 13:25~13:40 Future leadership of AOS - Korea  ±è¿­È«(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 13:40~13:55 Future leadership of AOS - India  Sanjeev Misra(King George) 
±³À°½Ã°£ 06-17 Room A 13:55~14:10 Future leadership of AOS - China  Ying Wang(China Anti-Cancer Association, China) 
±³À°½Ã°£ 06-17 Room A 14:10~14:25 Future leadership of AOS - Japan  Kazuhiro Yoshida(Gifu University, Graduate School of Medicine, Japan) 
Åä·Ð 06-17 Room A 14:25~15:05 Panel Discussion  () 
±³À°½Ã°£ 06-17 Room B 13:25~13:50 Immunologic resistance mechanisms of cancer immunotherapy  ½ÅÀÇö(KAIST) 
±³À°½Ã°£ 06-17 Room B 13:50~14:15 Immunotherapy resistance and its overcoming strategy in lung cancer  À̼¼ÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 14:15~14:40 Immunotherapy resistance and its overcoming strategy in gastric cancer  Narikazu Boku(University of Tokyo, Japan) 
±³À°½Ã°£ 06-17 Room B 14:40~15:05 Immunotherapy combination therapy for immune checkpoint inhibitor-resistant cancer  Hussein A. Tawbi(MD Anderson Cancer Center, USA) 
±³À°½Ã°£ 06-17 Room D 13:25~13:50 Landscape and function of multiple mutations within individual oncogenes.  Keisuke Kataoka(Keio University School of Medicine, Japan) 
±³À°½Ã°£ 06-17 Room D 13:50~14:15 Extrachromosomal DNA in multiple cancers  ±èÈÆ(¼º±Õ°ü´ë ¾à´ë) 
±³À°½Ã°£ 06-17 Room D 14:15~14:40 Profiling of circulating tumor DNA  Iain Tan(Genome Institute of Singapore, Singapore) 
±³À°½Ã°£ 06-17 Room D 14:40~15:05 Functional mutation pairs in cancer genomes  ±èŹÎ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room E 13:25~13:50 Molecular biology of CNS metastases  °ûÈ£½Å(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room E 13:50~14:15 Targeted therapy for advanced cancer with CNS metastases  ±èÇý·Ã(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room E 14:15~14:40 Local treatment for CNS metastases in the targeted therapy era  ±è¿µÁØ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room E 14:40~15:05 RANO response criteria for brain and leptomeningeal metastases  ÃÖ½ÂÈ«(¼­¿ïÀÇ´ë) 
È޽Ġ06-17  15:05~15:25 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 15:25~15:50 Lung cancer screening  Pan-Chyr Yang(National Taiwan University, Taiwan) 
±³À°½Ã°£ 06-17 Room A 15:50~16:15 Surgical treatment  Hisao Asamura(Keio University School of Medicine, Japan) 
±³À°½Ã°£ 06-17 Room A 16:15~16:40 Radiation treatment  Zhengfei Zhu(Fudan University Shanghai Cancer Center, China) 
±³À°½Ã°£ 06-17 Room A 16:40~17:05 Medical treatment  ¾È¸íÁÖ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 15:25~15:55 Targeting DNA damage pathway in advanced cancers  David Tan(National University of Singapore, Singapore) 
±³À°½Ã°£ 06-17 Room B 15:55~16:25 Mechanisms of resistance to PARP inhibitors in advanced cancers  ÀÌ°æÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 16:25~16:55 PARP inhibition in future  Nicola Jane Curtin(Newcastle University Centre for Cancer, UK) 
Åä·Ð 06-17 Room B 16:55~17:05 Q&A Discussion  () 
±³À°½Ã°£ 06-17 Room C 15:25~17:05 ´ëÇѾÏÇÐȸ°¡ ÁÖÃàÀÌ µÇ´Â Cancer Guideline ±¸Ãà  ¹ÌÁ¤() 
±³À°½Ã°£ 06-17 Room D 15:25~15:50 Evolution of cervical cancer treatment with the emergence of immune checkpoint inhibitors  Masahiro Kagabu(Iwate Medical University, Japan) 
±³À°½Ã°£ 06-17 Room D 15:50~16:15 2020 WHO classification of cervical adenocarcinoma  ÀÌö(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-17 Room D 16:15~16:40 Recent advance of radiotherapy for cervical cancer  Sezin Yuce Sari(Hacettepe University Medical School, Turkey) 
±³À°½Ã°£ 06-17 Room D 16:40~17:05 DNA vaccine as a novel treatment for cervical cancer in future  ÃÖÀ±Áø(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-17 Room E 15:25~15:50 Past, present, future of palliative care in Japan  Yusuke Hiratsuka(Takeda General Hospital, Japan) 
±³À°½Ã°£ 06-17 Room E 15:50~16:15 Past, present, future of palliative care in Taiwan  Shao-Yi Cheng(College of Medicine, National Taiwan University, Taiwan) 
±³À°½Ã°£ 06-17 Room E 16:15~16:40 Recent efforts to expand horizons of palliative care in Korea  ±èÀ¯Á¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room E 16:40~17:05 Life-sustaining treatment states in Korean cancer patients after enforcement of act on decisions on life-sustaining treatment  ±ÇÁ¤Çý(¼¼Á¾Ãæ³²´ëº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ : 2022-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ¿Ü»óÇÐȸ The 9th Pan-Pacific Trauma Congress 2022 Korea (2022³â Á¦9Â÷ ȯÅÂÆò¾ç ±¹Á¦¿Ü»óÇмú´ëȸ)(1ÀÏÂ÷) : 2022-06-17
´ÙÀ½±Û Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ : 2022-06-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 3 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 6 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 8 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 5 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 10 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 4 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 1 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 4 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 3 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 5 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 3 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 7 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 3 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 7 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 4 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷